BerGenBio
Clinical-stage biopharma that developed selective AXL kinase inhibitors for cancer.
BGBIO | OL
Overview
Corporate Details
- ISIN(s):
- NO0012921180 (+2 more)
- LEI:
- 213800TYYFXKYF3V2A23
- Country:
- Norway
- Address:
- MØLLENDALSBAKKEN 9, 5009 BERGEN
- Website:
- https://www.bergenbio.com/
- Sector:
- Manufacturing
Description
BerGenBio was a clinical-stage biopharmaceutical company focused on developing first-in-class selective AXL kinase inhibitors. The company's therapeutic candidates targeted AXL as a potential cornerstone of therapy for aggressive, advanced, and treatment-resistant cancers. In October 2025, BerGenBio completed a merger with Oncoinvent ASA, and the combined entity was renamed Oncoinvent.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-02-25 18:58 |
BerGenBio announces discontinuation of 1L STK11M NSCLC study and exploration of…
|
English | 4.5 KB | ||
| 2025-02-25 18:58 |
BerGenBio avslutter 1L STK11m NSCLC-studie og vil utforske strategiske alternat…
|
Norwegian | 4.5 KB | ||
| 2025-02-24 07:13 |
BerGenBio - Disclosure of shareholding
|
English | 702 bytes | ||
| 2025-02-18 06:00 |
BerGenBio ASA: Invitation to fourth quarter 2024 results webcast
|
English | 2.7 KB | ||
| 2024-11-26 07:00 |
BerGenBio to Present Company Update at DNB Nordic Healthcare Conference
|
English | 2.5 KB | ||
| 2024-11-20 19:31 |
BerGenBio Appoints Olav Hellebø as CEO
|
English | 3.3 KB | ||
| 2024-11-13 06:00 |
BerGenBio Third Quarter Results 2024
|
English | 991.1 KB | ||
| 2024-11-13 06:00 |
BerGenBio Third Quarter Results 2024
|
English | 5.2 KB | ||
| 2024-11-06 06:00 |
BerGenBio ASA: Invitation to third quarter 2024 results webcast
|
English | 3.3 KB | ||
| 2024-10-10 19:31 |
CEO Martin Olin steps down
|
English | 2.5 KB | ||
| 2024-10-10 09:07 |
BerGenBio ASA: Minutes from Extraordinary General Meeting
|
Norwegian | 229.8 KB | ||
| 2024-10-10 09:07 |
BerGenBio ASA: Minutes from Extraordinary General Meeting
|
English | 1.6 KB | ||
| 2024-10-07 05:00 |
BerGenBio Announces Safety Data from Dose Escalation Phase 1b in First Line NSC…
|
English | 4.1 KB | ||
| 2024-09-19 13:00 |
BERGENBIO ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING
|
Norwegian | 224.2 KB | ||
| 2024-09-19 13:00 |
BERGENBIO ASA: NOTICE OF EXTRAORDINARY GENERAL MEETING
|
English | 3.4 KB |
Automate Your Workflow. Get a real-time feed of all BerGenBio filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BerGenBio
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BerGenBio via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
